Antagonism of endothelin actions
CA 2391818 A1 · Owner: Queen'S University At Kingston · Inventors: Heaton, Jeremy P. W.; Banting, James D.; Adams, Michael A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus NO appears to inhibit endothelin , activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an, endothelin antagonist to a patient in a 'normal' physiological state may result in specific, regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 13, 1997. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 13, 2017.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 13, 2019.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.